Locate your nearest distributor

Location:
Type:
Text search:
Username:
Password:
Forgot password?

News Archive

A new chance for a smoke-free life - Acetium® lozenges available across Finland

10.09.2018 13:31

Free of nicotine and side effects, Acetium offers a totally new option for those seeking to quit smoking. Its effectiveness as a help for quitting smoking has been known for some years, and the link was confirmed in an extensive study published last year 1. Now, the product has raised broad interest both in Finland and internationally. “Acetium® lozenges are available in Finland in pharmacies, R-kioski shops, well-stocked convenience stores and the Biohit online shop at www.biohitshop.fi,” says Semi Korpela, President & CEO. Read more...

The results of the migraine study will be delayed from the previously reported schedule

07.09.2018 15:00

The results of the migraine study will be delayed from the autumn 2018 which was reported in Biohit’s Half Year Financial Report (H1 2018). Read more

Biohit GastroPanel® accurately predicted the progression of atrophic gastritis and its transition to gastric cancer in a European multicenter trial

05.09.2018 10:10

A Dutch research group working at Erasmus University (Rotterdam), headed by internationally recognized professor Kuipers, together with Norwegian researchers has published an important study in a leading gastroenterology journal (GUT, 2018). GastroPanel proved to be an accurate predictor of incident gastric cancer. Read more

Retail Partner ApS to distribute Acetium® lozenge in Danmark and Sweden

03.09.2018 10:00

Biohit Oyj and Retail partner ApS have signed an agreement for the distribution of the smoking cessation product Acetium lozenge in Danmark and Sweden. Read more ...

Biohit Oyj Half Year Financial Report 2018

22.08.2018 09:30

Biohit Oyj Half Year Financial Report 22 August 2018 at 9:30 am local time (EET) Read more

Decisions of the Extraordinary General Meeting of Biohit Oyj

16.08.2018 17:00

Biohit Oyj Decisions of the Extraordinary General Meeting 16, 2018 at 17.00 local time (EET). Read more

Changes to Biohit Oyj’s management

10.08.2018 11:23

Lea Paloheimo, PhD (clinical biochemistry), born in 1951, was appointed as business development director at Biohit Oyj as of 6 August 2018. She continues being a member of Biohit Oyj's management team as in her previous role as Production & reasearch and Development Director at Biohit. Paloheimo has worked at Biohit since 2001. Before her career at Biohit, Paloheimo nworked as Chemist at Huslab, Salesmanager at Dasico A/S in Denmark, Researcher at Orion Diagnostica (Orion Corporation) and as a Chemist at the Clinical Chemistry department of United Laboratories Ltd. She...

Changes to Biohit Oyj’s management

30.07.2018 09:30

Adjunct professor (molecular mircobiology) and computer science engineer Minna Mäki (b. 1969) has been appointed R&D and production director and as a member of the Management Team of Biohit Oyj starting July 30th 2018. Mäki will report to CEO Semi Korpela. Read more

Biohit Oyj B-shares Subscribed with Stock Options I 2013

05.07.2018 09:30

A total number of 10,054 new Biohit Oyj B-shares have been subscribed for with stock options I 2013 between 7 February 2018 and 4 June 2018. These shares have been entered into the Trade Register on July 2, 2018, as of which date the new shares will establish equal shareholder rights with the company's existing B-shares. Public trading begins on NASDAQ Helsinki as of July 3, 2018 together with the existing B-shares. Read more...

Notice of Biohit Oyj’s extraordinary general meeting

02.07.2018 09:30

Biohit Oyj shareholders are invited to attend the Extraordinary General Meeting of Biohit Oyj to be held on Thursday, August 16, 2018 starting at 4:00 pm at Vanha Ylioppilastalo. Read more

Constitutive meeting of Biohit Oyj’s Board of Directors

19.06.2018 09:30

Biohit Oyj’s Board of Directors has in its meeting yesterday elected Mr Osmo Suovaniemi as the Chairman of the Board of Directors.a Read more

Biohit Oyj’s Stock Exchange Release on 31 May 2018

31.05.2018 09:30

On April 13, the company announced the potential expansion of Biohit Ltd’s ownership. Read more

Changes to Biohit Oyj’s Management Team

30.04.2018 11:00

Biohit Oyj, Stock exchange release, April 30, 2018 at 11:00 am local time (EET) M.Sc. (Econ) Jukka Kainulainen (b. 1982) has been appointed Chief Financial Officer and as a member of the Management Team of Biohit Oyj starting August 1st 2018. read more

Decisions of the Annual General Meeting of Biohit Oyj

25.04.2018 20:00

Biohit Oyj Decisions of the Annual General Meeting April 25, 2018 at 8:00 pm local time (EEST) The Annual General Meeting (AGM) of Biohit Oyj held on Wednesday April 25, 2018 adopted the financial statements of the parent company and the consolidated financial statements, and resolved to discharge the members of the Board of Directors and the CEO from liability for the financial year 2017. read more

BIOHIT OYJ’S OWNERSHIP IS EXPANDING

13.04.2018 09:30

Biohit Oyj Stock Exchange Release April 13, 2018 at 9:30 am local time (EEST) The company has become aware that Biohit Oyj’s ownership is possibly expanding. With the possible trade of shares, Biohit Oyj’s partner Biohit Healthcare (Hefei) Co. Ltd acquires Biohit Ltd’s A shares and listed B shares from Osmo Suovaniemi, his family and their respective Interlab Ltd at a price of EUR 4.26 per share. In the event of the transaction, Biohit Healthcare (Hefei) Co. Ltd has 33,2 % of total number of Biohit shares and 29.5 % of the voting rights based on shares. read...

NOTICE OF BIOHIT OYJ’S ANNUAL GENERAL MEETING

04.04.2018 09:30

Biohit Oyj Stock Exchange Release April 4, 2018 at 9:30 am local time (EEST) Biohit Oyj shareholders are invited to attend the company’s Annual General Meeting to be held on Wednesday, April 25, 2018 starting at 5:00 pm at Vanha Ylioppilastalo. The address is Mannerheimintie 3, 00100 Helsinki. The reception of shareholders registered for the meeting and the distribution of voting slips will commence at 4:00 pm. Coffee will be served. read more...

Publication of Biohit Oyj Annual Report 2017

03.04.2018 09:30

Biohit Oyj Annual Financial Report April 3, 2018 at 9:30 am local time (EET) Biohit Oyj’s Annual Report 2017 is published today in PDF format. The annual report contains financial statements for 2017, the Report of the Board of Directors and Corporate Governance Statements. Annual report is published in Finnish and English, and it can be read and downloaded from Biohit company website www.biohithealthcare.com/investors

Biohit Oyj B-shares Subscribed with Stock Options I 2013

12.03.2018 13:00

Biohit Oyj, Total number of voting rights and capital, March 12, 2018 at 1 p.m. (EEST) A total number of 2,435 new Biohit Oyj B-shares have been subscribed for with stock options I 2013 between 5 December 2017 and 6 February 2018. These shares have been entered into the trade register on March 12, 2018, as of which date the new shares will establish equal shareholder rights with the company's existing B-shares. Public trading is expected to begin on NASDAQ Helsinki as of March 13, 2018 together with the existing B-shares. Read more...

Quit smoking, nicotine free: Oriola to distribute Acetium® lozenge in Finland

12.03.2018 10:30

Biohit Oyj, Press release, March 12, 2018 at 10:30 am local time (EET) Biohit Oyj and Oriola Oy have signed an agreement for the distribution of the smoking cessation product, Acetium lozenge in Pharmacies and other Oriola sales channels in Finland. Launch date for the product will be announced later. read more

Biohit Group Financial Statement Release 2017

28.02.2018 09:30

Biohit Oyj Financial Statement Release, 28 February 2018 at 9:30 am local time (EET) SUMMARY January-December 2017 Net sales grew by 9.6 % compared to 2016 Net sales EUR 9.0 million (EUR 8.2 million) EBITDA EUR 7.9. million (EUR -3.0 million) Operative EBITDA EUR -0.4 million (EUR -1.9 million) Operating profit EUR 6.4 million (EUR -3.4 million) The profit for the reporting period was EUR 6.1 million (EUR -3.3 million) Net sales from international operations 95.7 % (92.2 %) of total net sales Equity ratio 91.3 % (83.0 %) July-December 2017 Net sale...

Montebello to distribute Biohit products in Norway

23.02.2018 10:00

Biohit Oyj Press release, February 23rd, 2018 at 10:00 a.m. local time (EET) Biohit Oyj and Montebello Diagnostics AS have signed an agreement for the distribution of Biohit diagnostic products in Norway. The contract has been signed for three years with a continuation option. read more

Biohit GastroPanel® test helps reducing unnecessary gastroscopies in pre-operative evaluation of the patients referred for bariatric surgery

22.02.2018 13:00

Biohit Oyj Press release, 22nd February, 2018 at 1:00 p.m. local time (EET) Bariatric (obesity) surgery has become increasingly common in Western countries as the ultimate means to reduce the excess weight in patients with morbid obesity. In Finland, almost a thousand such operations are performed every year and in Sweden eight times more, 30.000 in France and more than a quarter of a million in USA. A careful pre-operative evaluation is necessary for all patients to assess the status of their stomach, usually done by gastroscopy and biopsies. A recently published study from Tartu Univ...

Changes to Biohit Oyj’s Management Team

20.02.2018 09:30

Biohit Oyj Company release, 20th February, 2018 at 9.30 a.m. local time (EET) Biohit Oyj CFO Niklas Nordström is joining another company. Search for the new CFO is ongoing. read more

Dow BioMedica to distribute Biohit GastroPanel® in Korea

15.02.2018 09:30

Biohit Oyj Press release, 15th February, 2018 at 9.30 a.m. local time (EET) Biohit Oyj and Dow BioMedica have signed an agreement for the distribution of Biohit GastroPanel in Korea. The contract has been signed for four years with a continuation option. The registration will start during the 1st quarter of 2018. Read more

Quit smoking without nicotine: Pharmathen Hellas S.A. to distribute Acetium® lozenge in Greece

30.01.2018 12:45

Biohit Oyj Press release, January 30, 2018 at 12.45 p.m. local time (EET) Biohit Oyj and Pharmathen Hellas S.A. have signed an agreement for the distribution of the smoking cessation product Acetium lozenge in Greece. The contract has been signed for three years with a continuation option. The first deliveries of the product will be in early 2018. read more...

Biohit Oyj’s comments on its Chinese distributor’s announcement

05.01.2018 14:30

Biohit Oyj company release 5.1.2018 klo 14:30 local time (EEST) Biohit Oyj does not normally comment on its distributors or other third parties announcements, but due to details presented in the media and the potential effects this may have on the company’s share price Biohit Oyj gives out the following statement: Biohit Oyj’s distributor, a wholly Chinese owned Biohit HealthCare (Hefei) Co. Ltd has announced that it will expand its GastroPanel production capacity and that it will bring GastroPanel onto new technology platforms and instruments. read more...